Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
DOWNLOAD WHITEPAPER

In-vitro Bioassays to Accelerate Immuno-Oncology Candidate Selection

In recent years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. In addition to Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and Programmed cell death protein 1 (PD-1) blockade, a wide range of therapeutics with the potential to reverse the tumour-induced suppression are under development. Despite the first successes, only a relatively small portion of patients benefit from these treatments and it has been shown that combination therapies can improve the outcome.  

Download to find out more.

DOWNLOAD

Submit

DOWNLOAD WHITEPAPER

In-vitro Bioassays to Accelerate Immuno-Oncology Candidate Selection

In recent years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. In addition to Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and Programmed cell death protein 1 (PD-1) blockade, a wide range of therapeutics with the potential to reverse the tumour-induced suppression are under development. Despite the first successes, only a relatively small portion of patients benefit from these treatments and it has been shown that combination therapies can improve the outcome.  

Download to find out more.

DOWNLOAD

We just need a few more details

If you would like to hear from carefully selected third party companies, check this box
* denotes mandatory fields









Close
Close
Close

Go Top